« Return to News | Drug Sponsors

Sanofi: Genzyme unit may be smaller

Thursday, June 2, 2011 11:16 AM

Sanofi has told employees of Cambridge, Mass.-based Genzyme, the biotech Sanofi acquired in April, that they will have a new reporting structure within the parent company, according to The Boston Globe.

Sanofi CEO Christopher A. Viehbacher said earlier this year that Genzyme will retain its name and remain a standalone biotechnology unit within Sanofi.

But in an employee bulletin out this week, Sanofi said the Genzyme unit will be smaller and include only its personalized genetic health and multiple sclerosis operations.

Genzyme’s current oncology, biosurgery and renal operations will be integrated into Sanofi businesses, the bulletin said. It did not say if that move would involve job cuts. Genzyme currently employs about 4,500 in Massachusetts and 10,000 worldwide.

Sanofi said Viehbacher will continue as acting Genzyme CEO until September, when a new Genzyme CEO will be named.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.